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Summary We investigated whether pretreatment with geranylgeranylacetone (GGA), a potent
heat shock protein (HSP) inducer, could inhibit proinflammatory cytokine liberation and
nitric oxide (NO) production in lipopolysaccharide (LPS)-treated murine macrophages. The
levels of NO and tumor necrosis factor-α (TNF-α) released from murine macrophage RAW
264 cells were increased dose- and time-dependently following treatment with LPS (1 µg/ml).
GGA (80 µM) treatment 2 h before LPS addition significantly suppressed TNF-α and NO
productions at 12 h and 24 h after LPS, respectively, indicating that GGA inhibits activation
of macrophages. However, replacement by fresh culture medium before LPS treatment
abolished the inhibitory effect of GGA on NO production in LPS-treated cells. Furthermore,
GGA inhibited both HSP70 and inducible NO synthase expressions induced by LPS treatment
despite an HSP inducer. When it was examined whether GGA interacts with LPS and/or
affects expression of Toll-like receptor 4 (TLR4) and CD14 on the cell surface, GGA inhibited
the binding of LPS to the cell surface, while GGA did not affect TLR4 and CD14 expressions.
These results indicate that GGA suppresses the binding of LPS to the cell surface of macrophages,
resulting in inhibiting signal transduction downstream of TLR4.
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Introduction
Lipopolysaccharide (LPS), a major component of the outer
membrane of Gram-negative bacteria is a potent activator
of macrophages and a causal agent of endotoxin shock [1].
LPS is well known to induce production of proinflammatory
mediators such as tumor necrosis factor-α (TNF-α),
interleukin (IL)-1β, IL-6, reactive oxygen species (ROS)
and nitric oxide (NO), leading to death from endotoxin
shock in animal models [2, 3]. Moreover, in vitro studies
have demonstrated that LPS enhances cytokine and/or NO
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production in macrophages [4], microglial cells [5] and
endothelial cells [6]. The process of these cellular responses
involves recognition of LPS by Toll-like receptor (TLR) 4
on the surface of the host cells, followed by activation of
nuclear factor (NF)-κB [7]. TLR is a receptor family protein
related to innate immunity and to date, 13 TLRs have been
identified in mice and 10 in humans [7]. TLR4 has now been
established as the receptor for LPS. TLR4 consists of an
extracellular protein motif called leucine-rich repeats (LRR)
and a cytoplasmic signaling domain similar to type I IL-1
receptor, called Toll-IL-1 receptor (TIR) domain. LPS is
recognized by TLR4 and its signal is transduced, resulting in
the activation of NF-κB and the induction of interferon
(IFN). NF-κB is known to regulate transcriptions of many
inflammation-related proteins including cytokines [8]. It
increases the expression of inflammatory cytokines such as
TNF-α, IL-1β, IL-6 and IFN-γ to stimulate inflammatory
reaction [8]. The intracellular signaling pathways downstream
of TIR domain can be subdivided into myeloid differentiation
factor 88 (MyD88)-dependent and -independent ones, which
are responsible for early and later activation of NF-κB,
respectively [7]. Recently, it has been revealed that the
recognition of LPS by TLR4 requires myeloid differentiation
2 (MD-2) in addition to TLR4 itself [9]. As for the process
upstream of TLR4, LPS-binding protein (LBP) in the serum
removes LPS from the outer membrane of the bacteria and
forms complexes consisting of LPS, LBP and soluble CD14
(sCD14) [9]. These complexes deliver LPS to membrane-
bound CD14 (mCD14) and then LPS bound to mCD14 is
transferred to TLR4-MD-2 complex.
Geranylgeranylacetone (GGA), an acylic polyisoprenoid,
is an anti-ulcer drug developed in Japan [10] and known to
protect against organ and cell damages via its potent HSP-
inducing function [10–13]. Induction of heat shock protein
(HSP) 70 has been reported to reduce the production of
proinflammatory mediators [2, 14] and to protect against
a variety of organ damages [15,  16] including ischemia-
reperfusion injury [11] and apoptosis [17]. It is known that
the overexpression of HSP70 inhibits the production of
cytokines in macrophages activated by LPS [18]. Recently,
we have found that oral administration of GGA to rats
before LPS injection induces HSP70 in several organs,
inhibits production of proinflammatory cytokines and NO,
and prevents organ damages, resulting in improvement of
survival rates [12]. Furthermore, GGA reportedly inhibited
NF-κB activation, resulting in suppression of inducible NO
synthase (iNOS) expression in IL-1β-treated vascular
smooth muscle cells [19]. However, it is still unknown
whether the inhibitory effect of GGA on the production
of cytokines and NO in LPS-mediated endotoxin shock
model involves the direct action to inflammatory mediator-
producing cells such as macrophages, and if so, where GGA
works in TLR4 signaling pathway.
In the present study, we investigated whether GGA
inhibits LPS-induced macrophage activation, resulting in
suppression of inflammation, and whether the inhibition by
GGA was related to HSP induction. We demonstrated that
GGA inhibited the binding of LPS to the surface of
macrophages, resulting in suppression of cytokine liberation
and NO production regardless of its HSP-inducing activity.
Materials and Methods
Materials
GGA was provided by Eisai Co Ltd. (Tokyo, Japan).
GGA was dissolved in ethanol. Escherichia coli LPS
serotype O111:B4 was purchased from Sigma Chemical Co.
(St. Louis, MO). LPS was dissolved in distilled water. Lipid
A (E. coli) was purchased from Peptide Institute, Inc. (Osaka,
Japan). Lipid A was dissolved in dimethylsulfoxide. Fetal
calf serum (FCS) was purchased from PAA Laboratories
GmbH (Linz, Austria). Rabbit anti-HSP70 polyclonal anti-
body and Phycoerythrin (PE)-labeled anti-mouse TLR4-
MD-2 complex monoclonal antibody (TLR4-MD-2-PE mAb)
were purchased from Medical & Biological Laboratories
Co., Ltd. (Nagoya, Japan). Mouse anti-iNOS monoclonal
antibody and fluorescein isothiocyanate (FITC)-conjugated
rat anti-mouse CD14 monoclonal antibody (CD14-FITC
mAb) were purchased from BD Biosciences Pharmingen
(San Diego, CA). Anti-LPS monoclonal antibody (WN1
222-5) was purchased from HyCult biotechnology b.v.
(Uden, The Netherlands). FITC-conjugated goat anti-mouse
IgG antibody was purchased from American Qualex (San
Clemente, CA). Cardiolipin (CL) from bovine heart was
purchased from Avanti Polar Lipids Inc. (Alabaster, AL).
Dulbecco’s modified eagle medium (DMEM) was obtained
from Nissui Pharmaceutical Co., Ltd. (Tokyo, Japan). All
the other chemicals used were of analytical grade.
Cell cultures and treatments with LPS and GGA
RAW 264 murine macrophage cell line was obtained from
Riken BRC Cell Bank (Tsukuba, Japan), and grown in
DMEM supplemented with 10% heat-inactivated FCS,
2 mM glutamine and antibiotics (100 units/ml penicillin,
100 µg/ml streptomycin) at 37°C in a humidified incubator
with 5% CO2. All the experiments were performed using
DMEM containing 10% FCS unless described specifically.
The cells were seeded in a 24-well plate at a cell density
of 5 × 105 cells/well and incubated for 2 h at 37°C in an
atmosphere of 5% CO2/95% air. After non-adherent cells
were removed by washing with culture medium, attached
cells were exposed to LPS at concentrations ranging from 10
to 1000 ng/ml for periods of 4, 8, 12 or 24 h at 37°C under
5% CO2/95% air. When the timing of GGA addition was
preliminarily investigated, only 2-h treatment with GGA
suppressed NO production in RAW 264 cells after LPS amongGeranylgeranylacetone Inhibits Macrophage Activation
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the examined time periods (2, 4, or 8 h of incubation).
Therefore, 2-h treatment with GGA was selected in the
present study. GGA at concentrations of 20, 40 or 80 µM was
added into the medium 2 h before LPS administration. In some
experiments, the culture medium 2 h after GGA addition was
replaced by fresh culture medium to investigate the potential
effect of GGA on the process of LPS binding to TLR4.
To investigate the dependence of inhibitory effects of
GGA on serum proteins, cells were washed several times in
serum-free DMEM to completely remove soluble proteins
and resuspended in serum-free medium for LPS challenge.
Determination of nitrite
The nitrite in the culture medium was measured as an
index of NO production by means of Griess reaction [20].
The cells (5 × 105 cells/well) were plated on 24-well plates
and incubated in the presence of LPS and/or GGA for the
indicated time periods at 37°C under 5% CO2/95% air. The
culture supernatant collected from each well was centrifuged,
and the aliquot (100 µl) was mixed with 100 µl of Griess
reagent (50 µl of 1% sulfanilamide in 5% phosphoric acid,
followed by 50 µl of 0.1% N-1-naphthylethylendiamine
dihydrochloride in water) and the absorbance was measured
at 562 nm in a microplate reader.
Determination of TNF-α
The TNF-α in the culture supernatant was determined
with an enzyme-linked immunosorbent assay (ELISA) kit
(BioSource International, Camarillo, CA) according to the
manufacturer’s instructions.
Cell viability
The viability of RAW 264 cells after continuous exposure
to LPS and/or GGA was determined using a commercially
available Cell Quanti-BlueTM Cell Viability Assay Kit
(BioAssay Systems, Hayward, CA) according to the
manufacturer’s instructions.
Analysis of iNOS and HSP70 contents
iNOS and HSP contents were determined by Western
blotting as described previously [21, 22]. The cells harvested
were homogenized and 40 µg of protein from each sample
was separated by SDS polyacrylamide gel electrophoresis
with 7.5% polyacrylamide gel (for iNOS) or 12.5% (for
HSP70). The gels were electroblotted onto polyvinylidene
difluoride membranes. The membranes were incubated with
mouse anti-iNOS monoclonal antibody (1:2000) and rabbit
anti-HSP70 polyclonal antibody (1:10000), washed and then
incubated with horseradish-peroxidase-conjugated sheep anti-
mouse (Amersham Pharmacia Biotech, Buckinghamshire,
England) and goat anti-rabbit (Sigma Chemical Co., St.
Louis, MO) antibody, respectively. The immunoblot was
revealed with an ECLTM Western blotting analysis system
(Amersham Pharmacia Biotech, Buckinghamshire, England).
Western blots were quantified with NIH Image.
Determination of LPS bound to the cell surface
RAW 264 cells (2 × 106 cells/ml of DMEM) were
incubated in the absence or presence of 80 µM GGA for 2 h
at 37°C in 5% CO2 and further incubated for 30 min after
addition of 1 µg/ml LPS. After treatments, the cells were
washed with PBS twice, resuspended in staining buffer (PBS
containing 2.5% FCS, 100 units/ml penicillin and 100 µg/ml
streptomycin) and incubated for 15 min on ice in the presence
of anti-LPS monoclonal antibody (1:100). After washing
with staining buffer, the cells were incubated with goat anti-
mouse IgG-FITC (1:100) for 15 min on ice in the dark. The
cells were washed with PBS three times, resuspended in
PBS and analyzed with an Epics cytofluorometer (Beckman
Coulter, Inc., Fullerton, CA).
Flow cytometry of TLR4-MD-2 complex and CD14 on the
cell surface
The cells (2 × 106 cells/ml of DMEM) were incubated in
the absence or presence of 80 µM GGA for 2 h at 37°C in
5% CO2. After treatments, the cells were washed with PBS
three times, resuspended in 200 µl of staining buffer (PBS
containing 2.5% FCS, 100 units/ml penicillin and 100 µg/ml
streptomycin) and incubated with TLR4-MD-2-PE mAb at
the concentration of 1 µg/1 × 106 cells for 30 min on ice
in the dark. After washing with staining buffer, the cells
were incubated with CD14-FITC mAb (1 µg/1 × 106 cells)
for 30 min on ice in the dark. The cells were washed
with PBS, resuspended in PBS and analyzed with an Epics
cytofluorometer (Beckman Coulter, Inc., Fullerton, CA).
Binding of LPS to LBP
In vitro assay for inhibition by GGA or CL of LPS-LBP
binding was performed using a commercially available
EndoblockTM (Cell Sciences, Inc., Canton, MA) according to
the manufacturer’s instructions.
Protein assay
Protein contents were measured using BCA Protein Assay
Reagent Kit (Pierce Biotechnology Inc., Rockford, IL) with
bovine serum albumin as a standard.
Statistical evaluations
Data are expressed as mean ± standard error (SE).
Changes in variables for different assays were analyzed by
one-way ANOVA followed by post hoc Fisher’s PLSD test.
Differences were considered to be significant at p<0.05S. Mochida et al.
J. Clin. Biochem. Nutr.
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Results
Dose- and time-dependent production of NO and TNF-α in
RAW 264 cells by LPS stimulation
To determine the concentration of LPS required for inducing
production of NO and TNF-α in RAW 264 cells, we treated
the cells with LPS at concentrations ranging from 10 to
1000 ng/ml for 24 and 12 h, respectively (Fig. 1). LPS
induced NO production in a dose-dependent manner
(Fig. 1A). TNF-α concentration in medium also increased in
a dose-dependent manner (Fig. 1B). We next examined the
time course of changes in release of NO and TNF-α from
RAW 264 cells following treatment with LPS (1 µg/ml)
(Fig. 2). NO concentration in medium increased with time up
to 24 h (Fig. 2A). TNF-α level in medium also increased
time-dependently, reached a maximum at 12 h and decreased
at 24 h after LPS addition (Fig. 2B). These results were
consistent with those in the previous study that LPS treatment
of murine macrophages resulted in the early expression of
TNF-α and the subsequent synthesis of iNOS [23].
Effect of GGA on LPS-mediated NO and TNF-α production
in RAW 264 cells
To determine whether GGA can inhibit LPS-induced NO
and TNF-α production, we treated RAW 264 cells with GGA
over a concentration range of 0–80 µM 2 h before 1 µg/ml
LPS administration (Fig. 3). GGA inhibited LPS-induced
NO production in a dose-dependent manner. Treatment with
80 µM GGA significantly reduced NO concentration 24 h
after LPS by 34% in comparison with treatment with
LPS alone (Fig. 3A). Pretreatment of the cells with
Fig. 1.  Dose-dependent production of NO (A) and TNF-α (B) in
RAW 264 cells by LPS treatment. Cells were incubated
with LPS (10, 100, or 1000 ng/ml) for 24 h (A) or 12 h
(B) at 37°C under a 5% CO2 and 95% air atmosphere.
The levels of NO and TNF-α were measured as
described in Materials and Methods. Data points represent
the means ± SE (n = 3). ap<0.01 vs 0 ng/ml, bp<0.01 vs
10 ng/ml, cp<0.01 vs 100 ng/ml in (A). ap<0.01 vs 0 ng/
ml,  bp<0.05 vs 10 ng/ml, cp<0.01 vs 10 ng/ml, dp<0.01
vs 100 ng/ml in (B).
Fig. 2.  Time-dependent production of NO (A) and TNF-α (B) in
RAW 264 cells by LPS treatment. Cells were incubated
with LPS (1 µg/ml) for 4, 8, 12 or 24 h at 37°C under a
5% CO2 and 95% air atmosphere. The levels of NO and
TNF-α were measured as described in Materials and
Methods. Data points represent the means ± SE (n = 3).
ap<0.01 vs 0 h, bp<0.01 vs 12 h.Geranylgeranylacetone Inhibits Macrophage Activation
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GGA also inhibited LPS-mediated TNF-α production dose-
dependently (Fig. 3B). Treatments with 40 µM and 80 µM
GGA significantly inhibited TNF-α concentration by 19%
and 29%, respectively, compared with LPS alone (Fig. 3B).
Effect of GGA treatment on cell viability
To confirm that the inhibitory effect of GGA on LPS-
induced NO and TNF-α production is not due to GGA-
induced cell death, we examined the cell viability 24 h after
addition of GGA (20, 40 or 80 µM), LPS (10, 100 or
1000 ng/ml) or GGA (20, 40 or 80 µM) plus LPS (1 µg/ml)
to RAW 264 cells. Any treatment did not decrease cell
viability significantly, in comparison with untreated cell
control (data not shown).
Effect of GGA on LPS-mediated iNOS induction in RAW 264
cells
Induction of iNOS in RAW 264 cells 24 h after LPS
administration (1 µg/ml) was assessed by Western blot
analysis (Fig. 4). LPS increased iNOS contents 3.3-fold
in comparison with untreated cells. Treatments with GGA
at concentrations of 20, 40 and 80 µM 2 h before LPS
addition decreased the contents by 31%, 35% and 58%,
respectively in a dose-dependent manner, compared with
LPS alone.
Effect of GGA on LPS-mediated HSP70 induction in RAW
264 cells
Overexpression of HSP70 reportedly inhibited the
production of cytokines in macrophages activated by LPS
[18]. Since GGA is well known to be a potent HSP70
inducer [12,  13], we investigated whether the inhibitory
effect of GGA on LPS-induced NO and TNF-α production
in RAW 264 cells was ascribed to HSP70 induction by
GGA treatment (Fig. 5A). Treatment with GGA 2 h before
LPS administration inhibited LPS-triggered HSP70 induction
in a dose-dependent manner. Specifically, 80 µM GGA
suppressed the increase in HSP70 content by LPS to the
control level. Treating the cells with 80 µM GGA alone for
2 h did not enhance HSP70 protein expression (Fig. 5B).
Effect of replacement by fresh culture medium before LPS
administration on inhibition by GGA of NO production in
LPS-treated RAW 264 cells
When GGA (20, 40 or 80 µM) was added to the medium
Fig. 3.  Inhibitory effect of GGA on LPS-mediated production
of NO (A) and TNF-α (B). Cells were incubated in
the presence or absence of LPS (1 µg/ml) for 24 h (A)
or 12 h (B) at 37°C under a 5% CO2 and 95% air
atmosphere. GGA (0, 20, 40, or 80 µM) was added 2 h
before the addition of LPS. The levels of NO and TNF-α
were measured as described in Materials and Methods.
Data points represent the means ± SE (n = 3).  ap<0.05,
bp<0.01 vs LPS alone-treated cells.
Fig. 4.  Effect of GGA on LPS-mediated iNOS induction in
RAW 264 cells. Cells were incubated in the presence or
absence of LPS (1 µg/ml) for 24 h at 37°C under a 5%
CO2 and 95% air atmosphere. GGA (0, 20, 40, or
80 µM) was added 2 h before the addition of LPS. iNOS
level was analyzed by Western blotting, quantified
densitometrically and expressed as relative density to
control cells. Data points represent the means ± SE
(n = 3).  ap<0.01 vs control, bp<0.01 vs LPS alone,
cp<0.05 vs LPS alone, dp<0.05 vs LPS (1 µg/ml) + GGA
(80 µM).S. Mochida et al.
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2 h before LPS administration and subsequently culture
medium was replaced by fresh one without GGA just
before LPS addition, the inhibitory effect of GGA on NO
production induced by LPS in the cells was abolished
(Fig. 6).
Effect of GGA on binding of LPS to the cell surface
To investigate the effect of GGA on LPS binding to the cell
surface, we used flow cytometry with an anti-LPS monoclonal
antibody (Fig. 7). Cell surface LPS increased after LPS
stimulation. However, the LPS binding was inhibited when
LPS was added to the medium in the presence of GGA.
Effect of GGA on TLR4-MD-2 complex and CD14 expressions
on the surface of RAW 264 cells
We next examined the expression of TLR4-MD-2 complex
and CD14 on the cell surface of RAW 264 cells in the
presence or absence of GGA by using flow cytometry.
Treatment of the cells with GGA did not affect the cell
surface expression of TLR4-MD-2 complex and CD14 (data
not shown).
Effect of GGA on lipid A-mediated NO production in RAW
264 cells
To determine whether the inhibitory effect of GGA on
LPS-mediated macrophage activation is due to its action on
lipid A, we examined the effect of GGA on NO production
in lipid A-treated RAW 264 cells (Fig. 8). NO contents in the
medium increased dose-dependently 24 h after treatment of
RAW 264 cells with lipid A at doses of 0.01–100 ng/ml
(data not shown). Pretreatment of the cells with 80 µM GGA
significantly decreased NO concentration by 35% at 24 h
after lipid A (100 ng/ml) challenge in comparison with lipid
A alone, completely consistent with inhibitory effect of GGA
Fig. 5.  Effect of GGA on HSP70 induction in RAW 264 cells.
(A) Cells were incubated in the presence or absence of
LPS (1 µg/ml) for 24 h at 37°C under a 5% CO2 and
95% air atmosphere. GGA (0, 20, 40, or 80 µM) was
added 2 h before the addition of LPS. (B) Cells were
incubated in the presence or absence of GGA (80 µM)
for 2 h at 37°C under a 5% CO2 and 95% air atmosphere.
HSP70 level was analyzed by Western blotting, quantified
densitometrically and expressed as relative density to
control cells. Data points represent the means ± SE
(n = 3). ap<0.01 vs control, bp<0.01 vs LPS alone-treated
cells.
Fig. 6.  Effect of replacement by fresh culture medium before
LPS administration on inhibition by GGA of NO pro-
duction in LPS-treated RAW 264 cells. GGA (0, 20, 40,
or 80 µM) was added to the medium 2 h before LPS ad-
ministration and subsequently culture medium was re-
placed by fresh one without GGA just before LPS addi-
tion. Cells were further incubated in the presence of LPS
(1 µg/ml) for 24 h at 37°C under a 5% CO2 and 95% air
atmosphere. The level of NO in the medium was mea-
sured as described in Materials and Methods. Data
points represent the means ± SE (n = 3).Geranylgeranylacetone Inhibits Macrophage Activation
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on LPS-mediated NO production (Fig. 8, compare with
Fig. 3A).
Effect of serum on LPS-induced TNF-α release
Serum proteins such as soluble LBP and soluble CD14
play important roles in cell activation induced by LPS. To
investigate the involvement of serum proteins in the inhibitory
action of GGA, TNF-α production by RAW 264 cells was
determined in the presence or absence of serum (Fig. 9).
TNF-α release at 4 h after LPS (1 µg/ml) challenge under
serum-free condition reduced to one third of that in the
presence of serum. However, GGA significantly inhibited
TNF-α production regardless of the presence of serum.
Furthermore, GGA failed to suppress the binding of LPS to
LBP on in vitro study although CL as a positive control
strongly inhibited LPS-LBP binding (data not shown).
Discussion
The present study demonstrated for the first time that
GGA inhibited NO and cytokine release from macrophages
activated by LPS stimulation.
In our previous study, we found that GGA suppressed the
liberations of proinflammatory cytokines like TNF-α, IL-6
and MIP-2 as well as NO in LPS-injected rats and this effect
of GGA was related to the enhancement of HSP70 induction
in several organs after LPS injection [12]. In the present study,
we investigated whether anti-inflammatory effect of GGA
in endotoxin shock was ascribed to the inhibition against
macrophage activation in addition to the HSP induction in
several organs. GGA inhibited the production of NO and
TNF-α in LPS-stimulated RAW 264 murine macrophage
cells (Fig. 3). The transcriptions of iNOS and TNF-α are
regulated by NF-κB [8]. Recently, it has been reported that
Fig. 7.  Effects of GGA on binding of LPS to the cell surface in
RAW 264 cells. Cells were incubated with 80 µM GGA
for 2 h at 37°C and for further 30 min after addition of
LPS (1 µg/ml). Cells were washed, and stained with anti-
LPS antibody, followed by goat anti-mouse IgG-FITC. The
LPS fluorescence resulting from LPS binding to cells was
measured by using Epics cytofluorometer. Representative
data from three separate experiments are shown.
Fig. 8.  Inhibitory effect of GGA on lipid A-mediated NO pro-
duction in RAW 264 cells. Cells were incubated in the
presence or absence of Lipid A (LA) (100 ng/ml) for
24 h at 37°C under a 5% CO2 and 95% air atmosphere.
GGA (80 µM) was added 2 h before the addition of LA.
NO level was measured as described in Materials and
Methods. Data points represent the means ± SE (n = 3).
ap<0.01 vs LA alone-treated cells.
Fig. 9. TNF-α release from RAW 264 cells after LPS stimulation
in the presence or absence of serum and its inhibition by
GGA. Cells were incubated with LPS (1 µg/ml) in the
presence (closed column) or absence (open column) of
serum for 4 h at 37°C under a 5% CO2 and 95% air
atmosphere. GGA (80 µM) was added 2 h before the
addition of LPS. TNF-α level was measured as described
in Materials and Methods. Data points represent the
means ± SE (n = 3). ap<0.01 vs LPS alone-treated cells
in the presence of serum. bp<0.05 vs LPS alone-treated
cells in the absence of serum.S. Mochida et al.
J. Clin. Biochem. Nutr.
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GGA suppressed IL-1β-mediated NF-κB activation in
vascular smooth muscle cells, leading to the inhibition of
iNOS expression and subsequent NO production [19].
Therefore, we determined the effect of GGA on iNOS
expression in RAW 264 cells after LPS challenge. GGA
inhibited iNOS induction as well as production of NO and
TNF-α in LPS-treated RAW 264 cells (Fig. 4), suggesting
that GGA suppressed NF-κB activation in LPS-stimulated
macrophages as well as IL-1β-stimulated vascular smooth
muscle cells [19]. It has been shown that the production of
proinflammatory cytokines was inhibited by the HSP70
induction [2, 14]. Given that GGA is a potent HSP inducer,
it is suggested that anti-inflammatory action of GGA might
also be due to the induction of HSP70. In the present study,
unexpectedly treatment of RAW 264 cells with GGA before
LPS administration inhibited HSP70 induction after LPS
challenge (Fig. 5). These paradoxical results for HSP
inducer GGA can be explained as follows. It has been
reported that the HSP-inducing activity of GGA appears to
be due to enhancing the process of heat shock factor (HSF)
1 activation such as nuclear translocation, phosphorylation
and DNA binding activity of HSF1 rather than due to
directly stimulating HSP induction [24]. In other words,
GGA can primes the cells for HSP induction, but not induce
HSP expression unless stimulation is added. We examined
HSP70 protein expression in RAW 264 cells at 2 h after
GGA treatment. However, there was no difference in HSP70
status between GGA-treated and control cells (Fig. 5B).
Even though RAW 264 cells were primed with GGA in these
experiments, it is considered that the LPS stimulation signal
was not transduced to the inside of the cells in the presence
of GGA. Furthermore, replacement of medium before LPS
addition abolished the inhibitory effect of GGA on LPS-
mediated NO production in the cells. These results suggested
that GGA did not exhibit anti-inflammatory action via
enhancement of HSP70 induction but affected the process of
LPS binding to TLR4 on the cell surface when it was in
extracellular space and/or cell membrane, resulting in
suppression of iNOS and HSP70 expression after LPS
stimulation. The results of LPS binding assay revealed that
GGA inhibited the binding of LPS to the cell surface without
affecting the expression of TLR4-MD-2 complex and CD14
on the cell surface. It is known that serum proteins such as
LBP and sCD14 can interact with LPS [9]. LPS from E. coli
consists of the outer most O side chain with repeating sugar
units, which determines the LPS antigenic specificity, a core
oligosaccharide and the inner most layer, lipid A, which
is responsible for LPS toxicity [9]. Hexaacylated E. coli
lipid A has the highest cytokine-inducing capacity [25]. In
contrast, lipid A partial structures lacking one or more fatty
acids, like the lipid A precursor IVa (synthetic compound 406)
which carries only four fatty acids, is endotoxically inactive,
but may express strong antagonistic activity against LPS-
induced cell activation [26, 27]. Recently, CL which has
structural similarities to compound 406 with respect to the
net negative charge (-2) and number of acyl chains (4)
strongly inhibited LPS-induced TNF-α release by a
blockade of the binding of LPS to LBP [25]. Because
LBP has positive charges, it can bind negatively charged
lipids like CL, phosphatidylserine or phosphatidylinositol
[28]. On the other hand, oxidized phosphatidylcholine (PC)
reportedly inhibited the interaction of LPS with LBP and
CD14 although PC has a net charge of 0 [29]. Since GGA
is an acylic polyisoprenoid, we determined the effect of
GGA on LPS-LBP binding on in vitro study. However,
GGA did not block the binding of LPS to LBP. Furthermore,
GGA inhibited LPS-mediated TNF-α production in the
cells even under serum-free conditions. Thus, the acting
points by GGA are unlikely serum protein such as LBP and
sCD14. Additionally, since GGA inhibited lipid A-induced
NO production in RAW cells (Fig. 7), it seems likely that
GGA acts on lipid A but not the saccharides of LPS. Taken
together, the remaining potential mechanisms underlying the
inhibition of macrophage activation by GGA are the inhibition
of interaction of LPS (especially lipid A) with mCD14 and/
or TLR4-MD2 complex. These hypotheses remain to be
elucidated.
In conclusion, the present study demonstrated that the
inhibition by GGA of the LPS effects on macrophages was
mediated by interference of the binding of LPS to the cell
surface, but not its HSP70-inducing activity, thereby inhibiting
recognition of LPS by TLR4.
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